ES2279441T3 - Derivados de quinazolina. - Google Patents

Derivados de quinazolina. Download PDF

Info

Publication number
ES2279441T3
ES2279441T3 ES04768483T ES04768483T ES2279441T3 ES 2279441 T3 ES2279441 T3 ES 2279441T3 ES 04768483 T ES04768483 T ES 04768483T ES 04768483 T ES04768483 T ES 04768483T ES 2279441 T3 ES2279441 T3 ES 2279441T3
Authority
ES
Spain
Prior art keywords
alkyl
oxy
chloro
amino
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04768483T
Other languages
English (en)
Spanish (es)
Inventor
Robert Hugh Astrazeneca R & D Alderley Bradbury
Laurent Francois Andre Hennequin
Bernard Christophe Astrazeneca Pharma Barlaam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2279441T3 publication Critical patent/ES2279441T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Structural Engineering (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES04768483T 2003-09-19 2004-09-15 Derivados de quinazolina. Expired - Lifetime ES2279441T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03292309 2003-09-19
EP03292309 2003-09-19
EP04291248 2004-05-14
EP04291248 2004-05-14

Publications (1)

Publication Number Publication Date
ES2279441T3 true ES2279441T3 (es) 2007-08-16

Family

ID=34379392

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04768483T Expired - Lifetime ES2279441T3 (es) 2003-09-19 2004-09-15 Derivados de quinazolina.

Country Status (32)

Country Link
US (2) US8318752B2 (enExample)
EP (1) EP1667992B1 (enExample)
JP (2) JP4036885B2 (enExample)
KR (1) KR101262442B1 (enExample)
CN (1) CN1882569B (enExample)
AR (1) AR045762A1 (enExample)
AT (1) ATE352550T1 (enExample)
AU (1) AU2004274227B2 (enExample)
BR (1) BRPI0414532B1 (enExample)
CA (1) CA2538752C (enExample)
CO (1) CO5680435A2 (enExample)
CY (1) CY1106405T1 (enExample)
DE (1) DE602004004553T2 (enExample)
DK (1) DK1667992T3 (enExample)
ES (1) ES2279441T3 (enExample)
HR (1) HRP20070113T3 (enExample)
IL (1) IL174284A (enExample)
IS (1) IS2545B (enExample)
MX (1) MXPA06003113A (enExample)
MY (1) MY138851A (enExample)
NO (1) NO333904B1 (enExample)
NZ (1) NZ545913A (enExample)
PL (1) PL1667992T3 (enExample)
PT (1) PT1667992E (enExample)
RU (1) RU2370494C2 (enExample)
SA (1) SA04250296B1 (enExample)
SI (1) SI1667992T1 (enExample)
TW (1) TWI342879B (enExample)
UA (1) UA83252C2 (enExample)
UY (1) UY28522A1 (enExample)
WO (1) WO2005028469A1 (enExample)
ZA (1) ZA200602264B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
US7569577B2 (en) 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
JP4036885B2 (ja) 2003-09-19 2008-01-23 アストラゼネカ アクチボラグ キナゾリン誘導体
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
US20070043010A1 (en) * 2003-09-25 2007-02-22 Astrazeneca Uk Limited Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
ATE413389T1 (de) 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
CN101124228B (zh) * 2004-12-14 2011-06-15 阿斯利康(瑞典)有限公司 用作抗肿瘤药物的吡唑并嘧啶化合物
EP1856095B1 (en) * 2005-02-26 2011-08-24 AstraZeneca AB Quinazoline derivatives as tyrosine kinase inhibitors
CN101175733A (zh) * 2005-05-12 2008-05-07 黄文林 一种酪氨酸激酶抑制剂、其制备方法及作为抗肿瘤药物的应用
WO2007029251A2 (en) * 2005-09-06 2007-03-15 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase
JP2009518450A (ja) * 2005-12-12 2009-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式複素環化合物、その化合物を含む薬剤、その使用及び製造方法
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
RS52573B (sr) 2008-02-07 2013-04-30 Boehringer Ingelheim International Gmbh Spirociklični heterocikli, lekovi koji sadrže navedeno jedinjenje, njihova primena i postupak za njihovu proizvodnju
WO2009138780A2 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Therapeutic treatment - 355
WO2009138779A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline
BRPI0912170A2 (pt) * 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
US8450482B2 (en) * 2009-04-23 2013-05-28 Astrazeneca Ab Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline
CN102060875B (zh) * 2009-11-18 2014-03-12 天津药物研究院 喹唑啉衍生物、制备方法和用途
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
CN103012367A (zh) * 2011-09-22 2013-04-03 北大方正集团有限公司 一种喹啉衍生物
CN103012368A (zh) * 2011-09-22 2013-04-03 北大方正集团有限公司 喹啉衍生物
TWI577671B (zh) 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
EP3342770B1 (en) 2013-03-06 2022-03-30 AstraZeneca AB Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
JP6704422B2 (ja) 2015-03-20 2020-06-03 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. キナゾリン誘導体の塩およびその製造方法
US10710968B2 (en) 2016-01-13 2020-07-14 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof
MX2022005388A (es) 2019-11-06 2022-05-24 Yuhan Corp Compuestos de pirrolidina y piperidina.

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985749A (en) 1975-12-22 1976-10-12 Eastman Kodak Company Process for preparation of 4-aminoquinazoline
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4332420A (en) 1980-01-11 1982-06-01 Coski William D Reciprocably supported dual drive member and features thereof
GB2160201B (en) 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
KR910006138B1 (ko) 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4921863A (en) 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
JPH0436885A (ja) * 1990-05-31 1992-02-06 Sharp Corp 光学式文字読取装置
US5252586A (en) 1990-09-28 1993-10-12 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
DE4105503A1 (de) 1991-02-19 1992-08-20 Jenapharm Gmbh Ausgangsverbindungen zur herstellung von calcitriol sowie dessen abkoemmlingen, verfahren zur herstellung dieser ausgangsverbindungen sowie zwischenprodukte fuer dieses verfahren
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
BR9406724A (pt) 1993-05-26 1996-02-06 Syntex Inc Novos ligantes de receptores 1-fenilalcanona 5-ht4
US5395846A (en) 1993-06-25 1995-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
TW321649B (enExample) 1994-11-12 1997-12-01 Zeneca Ltd
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2216169C (en) 1996-01-31 2007-01-23 Gist-Brocades B.V. Use of compositions comprising stabilized biologically effective compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
US6004967A (en) 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
GB9626589D0 (en) 1996-12-20 1997-02-05 Prolifix Ltd Peptides
US5929080A (en) 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
JP4245682B2 (ja) 1997-12-25 2009-03-25 協和発酵キリン株式会社 キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤
US6384223B1 (en) 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
AU3281600A (en) 1999-02-27 2000-09-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6627651B1 (en) 1999-05-07 2003-09-30 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
US6126917A (en) 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
WO2000078735A1 (de) 1999-06-21 2000-12-28 Boehringer Ingelheim Pharma Kg Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
GB9925958D0 (en) 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
CA2401778C (en) 2000-02-29 2010-12-21 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US20030152572A1 (en) 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
US20040110743A1 (en) 2000-05-19 2004-06-10 Masaomi Miyamato -Secretase inhibitors
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US20020082270A1 (en) 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042061A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6617329B2 (en) 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
DE10042060A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6653305B2 (en) 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE10042062A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung
US6740651B2 (en) 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
CN1543452A (zh) 2000-09-01 2004-11-03 Fmc 1,4-二取代苯杀虫剂
BR0113625A (pt) 2000-09-08 2003-07-22 Pharmacia Italia Spa Exemestano como agente de quimioprevenção
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
US20030158196A1 (en) 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
EP1339458B1 (en) * 2000-11-22 2007-08-15 Novartis AG Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
CA2431322A1 (en) 2000-12-11 2002-06-20 Eiji Nara Medicinal compositions having improved absorbability
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
TWI309647B (enExample) 2001-02-21 2009-05-11 Mitsubishi Tanabe Pharma Corp
US6562319B2 (en) 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
WO2002094790A1 (en) 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
AU2002342051B2 (en) 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
JP2003246780A (ja) 2001-12-17 2003-09-02 Eisai Co Ltd 含窒素芳香環化合物の製造方法
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
WO2003066602A1 (en) 2002-02-06 2003-08-14 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
AU2003226705B2 (en) * 2002-03-30 2008-11-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US7312214B2 (en) 2002-05-10 2007-12-25 Bristol-Myers Squibb Company 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors
EP1511769A2 (en) 2002-05-15 2005-03-09 Birgit Luber Egf receptor antagonists in the treatment of gastric cancer
US20040038856A1 (en) 2002-05-17 2004-02-26 Sarvajit Chakravarty Treatment of fibroproliferative disorders using TGF-beta inhibitors
WO2003101491A1 (en) 2002-06-03 2003-12-11 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
CA2494367A1 (en) 2002-07-25 2004-02-05 Scios Inc. Methods for improvement of lung function using tgf-.beta. inhibitors
AU2003247141A1 (en) 2002-08-01 2004-02-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
AU2003257666A1 (en) 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
JPWO2004060400A1 (ja) 2003-01-06 2006-05-11 那波　宏之 上皮成長因子受容体を分子標的とする抗精神病薬
DE10300097A1 (de) 2003-01-07 2004-07-22 Bayer Ag Kupfer-Komplexe und ihre Verwendung
DE10300098A1 (de) 2003-01-07 2004-07-15 Bayer Ag Kupfer-Carben-Komplexe und ihre Verwendung
MXPA05008450A (es) 2003-02-10 2005-10-18 Vertex Pharma Procesos para la preparacion de n-heteroaril-n-aril-aminas mediante reaccion de un ester de acido n-aril-carbamico con un halo-heteroarilo y procesos analogos.
CA2518716A1 (en) 2003-03-11 2005-01-13 Dana-Farber Cancer Institute Inhibition of viral pathogenesis
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
RU2431500C2 (ru) 2003-06-09 2011-10-20 Самуэль ВАКСАЛ Способ ингибирования рецепторных тирозинкиназ с помощью внеклеточного антагониста и внутриклеточного антагониста
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
BRPI0413066A (pt) 2003-07-29 2006-10-17 Astrazeneca Ab derivado de quinazolina, ou um sal farmaceuticamente aceitável, ou um éster farmaceuticamente aceitável do mesmo, da fórmula i, uso e processo para a preparação do mesmo, composto, composição farmacêutica, e, métodos para a produção de um efeito antiproliferativo em um animal de sangue quente, para a prevenção ou tratamento de um tumor, para prover um efeito inibitório de tirosina quinase de egfr seletivo, e para tratar um cáncer em um animal de sangue quente
JP2007502807A (ja) 2003-08-18 2007-02-15 ファイザー・プロダクツ・インク Ｅｒｂｂ２抗がん剤の投与スケジュール
DE602004004811T2 (de) 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
JP4036885B2 (ja) 2003-09-19 2008-01-23 アストラゼネカ アクチボラグ キナゾリン誘導体
US20070043010A1 (en) 2003-09-25 2007-02-22 Astrazeneca Uk Limited Quinazoline derivatives
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
US20050096332A1 (en) * 2003-10-30 2005-05-05 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法

Also Published As

Publication number Publication date
NZ545913A (en) 2009-01-31
WO2005028469A1 (en) 2005-03-31
ZA200602264B (en) 2007-12-26
MXPA06003113A (es) 2006-06-20
CN1882569B (zh) 2010-09-29
NO333904B1 (no) 2013-10-14
IL174284A0 (en) 2006-08-01
UA83252C2 (uk) 2008-06-25
RU2006112845A (ru) 2007-11-10
KR20060089742A (ko) 2006-08-09
JP2007505875A (ja) 2007-03-15
IS8412A (is) 2006-04-12
RU2370494C2 (ru) 2009-10-20
PL1667992T3 (pl) 2007-05-31
KR101262442B1 (ko) 2013-05-08
SI1667992T1 (sl) 2007-06-30
TW200526629A (en) 2005-08-16
JP2008037874A (ja) 2008-02-21
BRPI0414532A (pt) 2006-11-07
AR045762A1 (es) 2005-11-09
TWI342879B (en) 2011-06-01
BRPI0414532B1 (pt) 2018-06-05
SA04250296B1 (ar) 2008-07-14
HK1091489A1 (en) 2007-01-19
US20120329795A1 (en) 2012-12-27
UY28522A1 (es) 2005-04-29
AU2004274227A1 (en) 2005-03-31
CO5680435A2 (es) 2006-09-29
CN1882569A (zh) 2006-12-20
US8318752B2 (en) 2012-11-27
EP1667992B1 (en) 2007-01-24
NO20061327L (no) 2006-04-05
ATE352550T1 (de) 2007-02-15
DE602004004553D1 (de) 2007-03-15
DE602004004553T2 (de) 2007-10-25
US20080096881A1 (en) 2008-04-24
CY1106405T1 (el) 2011-10-12
PT1667992E (pt) 2007-04-30
IS2545B (is) 2009-10-15
JP4036885B2 (ja) 2008-01-23
HRP20070113T3 (en) 2007-04-30
CA2538752A1 (en) 2005-03-31
AU2004274227B2 (en) 2008-04-24
IL174284A (en) 2014-09-30
EP1667992A1 (en) 2006-06-14
MY138851A (en) 2009-08-28
CA2538752C (en) 2011-08-02
DK1667992T3 (da) 2007-04-30

Similar Documents

Publication Publication Date Title
ES2279441T3 (es) Derivados de quinazolina.
ES2281007T3 (es) Derivados de quinazolina.
ES2346135T3 (es) Derivados de 4-anilino quinazolina como agentes antiproliferativos.
ES2305844T3 (es) Derivados de quinazolina como inhibidores de tirosina cinasa.
ES2328696T3 (es) Derivados de quinazolina.
US7148230B2 (en) Quinazoline derivatives
ES2329576T3 (es) Derivados de 4-anilino-quinazolina como agentes antiproliferativos.
US20070099943A1 (en) Quinazoline derivatives
CN101659658B (zh) 氰基取代的喹啉衍生物
CN101659657B (zh) 氰基取代的喹啉衍生物及其制备方法和用途
HK1091489B (en) Quinazoline derivatives
HK1091486B (en) Quinazoline derivatives